CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Campbell, M. L.
Right arrow Articles by Arlinghaus, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Campbell, M. L.
Right arrow Articles by Arlinghaus, R. B.

Cell Growth & Differentiation, Vol 4, Issue 7 581-588, Copyright © 1993 by American Association of Cancer Research


ARTICLES

Inhibition of phosphorylation of p160 BCR within p210 BCR-ABL complexes during early stages of phorbol ester-induced differentiation of K562 cells

ML Campbell, D Lu, JQ Guo and RB Arlinghaus
Department of Molecular Pathology, University of Texas, M.D. Anderson Cancer Center Houston 77030.

The kinase activity of the BCR-ABL gene product is known to be down-regulated in K562 cells treated with low concentrations of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA). The reduction of BCR-ABL kinase activity is followed by the loss of cell proliferation and progression to a more differentiated state. We have previously demonstrated that K562 cells possess protein complexes that contain p210 BCR-ABL and p160 BCR (M. L. Campbell, W. J. Li, and R. B. Arlinghaus, Oncogene, 5: 773-776, 1990). We performed experiments to determine whether BCR-ABL/BCR complexes were disrupted prior to alterations in cell growth and differentiation effects in TPA-treated K562 cells. Our results indicate that BCR-ABL/BCR complexes disappeared at precisely the same time after TPA treatment as the loss of autophosphorylation activity exhibited by total p210 BCR-ABL, which occurred 16-19 h after TPA treatment. The loss of kinase activity preceded the loss of p210 BCR by more than 24 h. A degraded form of p210 BCR-ABL (about 175 kilodaltons) accounted for the residual autophosphorylation activity seen during the later phases of kinase inactivation following TPA treatment, and this form was preferentially sequestered within BCR-ABL/BCR complexes. This altered BCR-ABL protein, although able to autophosphorylate, had reduced ability to phosphorylate p160 BCR. We conclude that 15 nM TPA treatment of K562 cells initiates effects that simultaneously interfere with the phosphorylation of p160 BCR in BCR-ABL complexes and inactivates the autophosphorylation activity of the full length BCR-ABL protein.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
BloodHome page
K. A. Weigel-Kelley, M. C. Yoder, and A. Srivastava
{alpha}5{beta}1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of {beta}1 integrin for viral entry
Blood, December 1, 2003; 102(12): 3927 - 3933.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
I. Lindner, M. A. Kharfan-Dabaja, E. Ayala, D. Kolonias, L. M. Carlson, Y. Beazer-Barclay, U. Scherf, J. H. Hnatyszyn, and K. P. Lee
Induced Dendritic Cell Differentiation of Chronic Myeloid Leukemia Blasts Is Associated with Down-Regulation of BCR-ABL
J. Immunol., August 15, 2003; 171(4): 1780 - 1791.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1993 by the American Association of Cancer Research.